Skip to main content
Ania Jastreboff, MD, Endocrinology, New Haven, CT

Ania M Jastreboff MD PhD

Diabetes, Obesity, Pediatric Endocrinology


Associate Professor, Internal Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine

Join to view full profile
  • 333 Cedar St, PO Box 208020Yale University School Of Medicine - EndocrinologyNew Haven, CT 06510

  • Phone+1 203-737-1932

Dr. Jastreboff is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Jastreboff is an Associate Professor at Yale University School of Medicine. She is board certified in Obesity Medicine, adult Endocrinology and Metabolism, and Pediatric Endocrinology. She is nationally/internationally recognized in the Obesity Medicine field for developing Clinical Practice Guidelines (2016) for The Comprehensive Care of Patients with Obesity (AACE/ACE), educating the next generation of Obesity Medicine physicians by teaching annually at the world renowned Harvard Blackburn Treating Obesity course and the Columbia/Cornell Obesity course, and conducting cutting-edge clinical translational obesity research. Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications.

    Clinically, Dr. Jastreboff specializes in sophisticated use of anti-obesity medication combinations to help patients reach their weight and health goals. She mainly sees patients for obesity treatment and weight management.


    Dr. Jastreboff completed her PhD at Yale University's Investigative Medicine Program focused on translational and clinical investigation with a dissertation entitled “Neural Response to Food Cues and Stress in Individuals with Obesity".

    Dr. Jastreboff's research has been supported by NIH/NIDDK (K23, R01), American Diabetes Association (ADA), and industry funded multi-center clinical trials.

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2007 - 2011
  • University of Maryland
    University of MarylandResidency, Internal Medicine/Pediatrics, 2002 - 2006
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2025 - 2027
  • CT State Medical License
    CT State Medical License 2010 - 2027
  • MD State Medical License
    MD State Medical License 2006 - 2008
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
  • Obesity Medicine
    American Board of Obesity Medicine Obesity Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Novo Nordisk STEP Young Phase 3 Data: 40.4% of Children Living with Obesity Achieved a BMI Below the Obesity Threshold with Semaglutide and Lifestyle Modification
    Novo Nordisk STEP Young Phase 3 Data: 40.4% of Children Living with Obesity Achieved a BMI Below the Obesity Threshold with Semaglutide and Lifestyle ModificationSeptember 7th, 2026
  • Retatrutide Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1
    Retatrutide Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1May 21st, 2026
  • A New Concern About Weight Loss Drugs: What if They Work Too Well?
    A New Concern About Weight Loss Drugs: What if They Work Too Well?February 18th, 2026

Grant Support

  • Semaglutide Dose Effects on Metabolic and Stress Hormones, Craving and Alcohol Use OutcomesYALE UNIVERSITY2026–2031
  • GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weightYALE UNIVERSITY2013–2025
  • GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weightYALE UNIVERSITY2013–2025
  • Preventing Childhood Obesity Through a Mindfulness-based Parent Stress InterventionYALE UNIVERSITY2018–2024
  • Preventing Childhood Obesity Through a Mindfulness-based Parent Stress InterventionYALE UNIVERSITY2018–2024

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: